NCT05128942View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH

PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Congenital Adrenal Hyperplasia21-OHD
Interventions
DRUG

Tildacerfont

Oral tablet formulation taken once daily in combination with glucocorticoid therapy.

Trial Locations (13)

14203

Spruce Study Site, Buffalo

22903

Spruce Study Site, Charlottesville

23284

Spruce Study Site, Richmond

29203

Spruce Study Site, Columbia

55454

Spruce Study Site, Minneapolis

60611

Spruce Study Site, Chicago

75231

Spruce Study Site, Dallas

76104

Spruce Study Site, Fort Worth

78539

Spruce Study Site, Edinburg

84113

Spruce Study Site, Salt Lake City

92123

Spruce Study Site, San Diego

95821

Spruce Study Site, Sacramento

02903

Spruce Study Site, Providence

Sponsors

Lead Sponsor

Spruce Biosciences
All Listed Sponsors
lead

Spruce Biosciences

INDUSTRY

NCT05128942 - A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH | Biotech Hunter | Biotech Hunter